MGNX Earnings & Financial Statements
MacroGenics, Inc.
$3.64
-$0.13(-3.45%)
48
Overall
60
Value
50
Tech
34
Quality
Market Cap
$240.15M
Volume
630.16K
52W Range
$1.29 - $5.08
Target Price
$8.00
MGNX earnings and financial statements: MacroGenics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MGNX Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $149.50M | $149.96M | $58.75M | $150.02M | $75.64M |
| Cost of revenue | $36.01M | $847.0K | $619.0K | $7.38M | $2.65M |
| Operating income | -$72.84M | -$110.58M | -$168.24M | -$121.42M | -$202.79M |
| EBITDA | -$59.61M | -$57.37M | $1.85M | -$115.28M | -$190.86M |
| Net income | -$74.62M | -$66.97M | -$9.06M | -$119.76M | -$202.12M |
| EPS (diluted) | $-1.18 | $-1.07 | $-0.15 | $-1.95 | $-3.37 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $256.85M | $261.65M | $298.42M | $280.47M | $335.25M |
| Total liabilities | $201.25M | $145.60M | $145.81M | $138.46M | $95.63M |
| Shareholders’ equity | $55.59M | $116.06M | $152.61M | $142.01M | $239.62M |
| Cash and equivalents | $57.22M | $182.84M | $100.96M | $108.88M | $123.47M |
| Long-term debt | $31.59M | $32.60M | $30.20M | $30.11M | $20.79M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$81.04M | -$68.37M | -$78.20M | -$86.96M | -$143.83M |
| Capital expenditure | -$1.90M | $36.45M | -$1.76M | -$3.62M | -$6.20M |
| Free cash flow | -$82.95M | -$72.08M | -$79.97M | -$90.58M | -$150.03M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MGNX | $3.64 | -3.4% | 630.16K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |